Charles Schwab’s Heaviest Healthcare Sector Stock Holdings

Wall St. Watchdog reveals information regarding Charles Schwab Investment Management’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 256 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $3.256 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011 reported holding 5,355,565 shares with a market value of $356,252,166. This comprised 1.09% of the total portfolio. On 09/30/2011 reported holding 5,419,727 shares with a market value of $345,182,405. This comprised 1.25% of the total portfolio. The net change in shares for this position over the two quarters is 64,162. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011 reported holding 17,655,967 shares with a market value of $363,712,927. This comprised 1.11% of the total portfolio. On 09/30/2011 reported holding 17,811,362 shares with a market value of $314,904,886. This comprised 1.14% of the total portfolio. The net change in shares for this position over the two quarters is 155,395. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011 reported holding 6,554,177 shares with a market value of $189,808,960. This comprised 0.58% of the total portfolio. On 09/30/2011 reported holding 7,291,141 shares with a market value of $228,795,998. This comprised 0.83% of the total portfolio. The net change in shares for this position over the two quarters is 736,964. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011 reported holding 6,777,576 shares with a market value of $239,180,663. This comprised 0.73% of the total portfolio. On 09/30/2011 reported holding 6,915,401 shares with a market value of $226,133,618. This comprised 0.82% of the total portfolio. The net change in shares for this position over the two quarters is 137,825. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011 reported holding 3,079,734 shares with a market value of $162,055,600. This comprised 0.5% of the total portfolio. On 09/30/2011 reported holding 3,141,982 shares with a market value of $160,680,958. This comprised 0.58% of the total portfolio. The net change in shares for this position over the two quarters is 62,248. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011 reported holding 3,578,306 shares with a market value of $134,293,820. This comprised 0.41% of the total portfolio. On 09/30/2011 reported holding 3,774,773 shares with a market value of $139,553,362. This comprised 0.5% of the total portfolio. The net change in shares for this position over the two quarters is 196,467. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011 reported holding 2,704,808 shares with a market value of $139,514,002. This comprised 0.43% of the total portfolio. On 09/30/2011 reported holding 2,709,672 shares with a market value of $124,970,070. This comprised 0.45% of the total portfolio. The net change in shares for this position over the two quarters is 4,864. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011 reported holding 2,276,451 shares with a market value of $132,830,912. This comprised 0.41% of the total portfolio. On 09/30/2011 reported holding 2,273,319 shares with a market value of $124,941,610. This comprised 0.45% of the total portfolio. The net change in shares for this position over the two quarters is -3,132. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Watson Pharmaceuticals Inc. (NYSE:WPI): On 06/30/2011 reported holding 1,563,126 shares with a market value of $107,433,655. This comprised 0.33% of the total portfolio. On 09/30/2011 reported holding 1,536,989 shares with a market value of $104,899,499. This comprised 0.38% of the total portfolio. The net change in shares for this position over the two quarters is -26,137. About Company: Watson Pharmaceuticals, Inc. develops, manufactures, and sells generic and brand name pharmaceutical products. The Company’s core focus is specialty products, nephrology, urology, and generic products.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011 reported holding 1,069,556 shares with a market value of $89,040,537. This comprised 0.27% of the total portfolio. On 09/30/2011 reported holding 937,501 shares with a market value of $77,231,330. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is -132,055. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.

(Note: Data regarding Charles Schwab Investment Management’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet